Signal
Terremoto Biosciences raises $108 million to advance AKT-targeting drug candidates
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-04-15 11:48 UTCUpdated 2026-04-15 15:05 UTC
rss
clinical_trialsbiotech_fundingdrug_development
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Terremoto Biosciences, a California biotech company focused on developing covalent inhibitors targeting the AKT pathway, announced a $108 million Series C funding round. The proceeds will fuel ongoing clinical trials, including a Phase 1 therapy already in testing, and support the advancement of an additional candidate expected to enter clinical trials within the year. This capital injection aims to broaden the company's drug development efforts against AKT1, a significant target in cancer treatment.
Entities
Terremoto Biosciences
Score total
0.99
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- Terremoto's recent Series C funding enables expansion of clinical programs this year.
- One therapy is already in Phase 1, with another candidate poised to enter trials soon.
- The biotech sector is increasingly focused on covalent drug modalities, highlighting Terremoto's strategic positioning.
Why it matters
- AKT is a critical target in oncology, and new inhibitors could address unmet medical needs.
- Significant funding rounds indicate investor confidence in Terremoto's drug development approach.
- Advancing multiple candidates to clinical trials accelerates potential therapeutic options.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: high
Recurring claims
- Terremoto Biosciences raised $108 million in Series C funding to support clinical trials of AKT1 inhibitors.
How sources frame it
- BioPharma Dive: neutral
- Fierce Biotech: neutral
All evidence
All evidence
Terremoto raises $108M to pursue development of drugs targeting AKT
BioPharma Dive · biopharmadive.com · 2026-04-15 15:05 UTC
Terremoto Biosciences has spelt out how the California biotech will use a $108 million series C round to continue its efforts to broaden the covalent drug alphabet.
Fierce Biotech · fiercebiotech.com · 2026-04-15 11:48 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- BioPharma Dive (1)
- Fierce Biotech (1)
Top origin domains (this list)
- biopharmadive.com (1)
- fiercebiotech.com (1)